Across 11,220 patients in seven trials, orforglipron showed no signal for liver injury

As orforglipron, the oral non-peptide GLP-1 receptor agonist from Eli Lilly, moves toward potential approval, a pooled safety analysis published this month in Diabetes, Obesity and Metabolism specifically examines its effects on the liver — a relevant question for any new oral medication, and one this analysis addresses using the full breadth of the drug's phase 3 program [s1].

The design

Researchers pooled data from seven orforglipron phase 3 clinical trials, covering both the weight-management and type 2 diabetes development programs, for up to 104 weeks including safety follow-up [s1]. The analysis included 11,220 total participants: 6,920 on orforglipron and 4,300 on pooled comparators (placebo, oral semaglutide, dapagliflozin, or insulin glargine, depending on the specific trial) [s1]. Trial eligibility required baseline liver enzymes (ALT/AST) below three times the upper limit of normal in the weight-management program and below five times the upper limit in the diabetes program [s1]. The analysis tracked continuous and categorical changes in liver enzymes, screened specifically for drug-induced liver injury using Hy's Law criteria (a standard regulatory framework combining elevated liver enzymes with elevated bilirubin to flag serious drug-induced liver injury), and summarized hepatic adverse events, including in a subgroup with elevated baseline liver enzymes [s1].

What it found

Orforglipron treatment was associated with mean reductions in ALT and AST — liver enzymes actually went down on average, not up [s1]. Categorical elevations in these enzymes were generally balanced between the orforglipron and comparator groups [s1]. Six orforglipron-treated participants (0.1%) and six comparator-treated participants (0.1%) met the combined criteria of ALT or AST at least three times the upper limit of normal alongside total bilirubin at least twice the upper limit — the Hy's Law threshold used to screen for serious drug-induced liver injury [s1]. Critically, alternative explanations accounted for all six orforglipron cases, meaning none were classified as meeting the criteria for drug-induced liver injury [s1]. The overall incidence of hepatic adverse events was balanced between orforglipron and comparators, and results were consistent whether participants started with normal or elevated baseline liver enzymes [s1].

Why an exact match between drug and placebo matters here

Finding identical case counts — six in each group — meeting the Hy's Law screening threshold, with the orforglipron cases specifically ruled out as drug-related after review, is about as clean a safety signal as a pooled analysis of this kind can produce. It means the analysis didn't just find a numerically similar but slightly-worse rate for orforglipron that required statistical argument to explain away — the raw counts matched, and the cases that did occur had documented alternative causes.

What the enzyme reductions likely reflect

The mean reduction in liver enzymes on orforglipron is consistent with what's broadly observed when patients lose significant weight through any effective method — liver enzyme improvement is a well-established downstream effect of weight loss itself, particularly relevant given that excess weight and metabolic dysfunction are drivers of fatty liver disease. The study's authors frame the aminotransferase trajectory as "consistent with the metabolic benefits of weight loss" [s1] rather than as a direct hepatoprotective drug effect distinct from the weight loss orforglipron produces.

What this doesn't establish

This is a pooled analysis of data collected within trials up to 104 weeks — a substantial window, but still short of the years-to-decades timeframe over which some rare drug-related liver injuries can take to manifest, particularly once a drug moves from a closely monitored trial population to broader real-world use with less frequent liver-function monitoring. This is Lilly-sponsored trial data, from trials designed with the specific liver-enzyme eligibility cutoffs described above, meaning the population studied already excluded people with more significantly elevated baseline liver function abnormalities.

What to watch

Post-marketing pharmacovigilance data once orforglipron reaches wider real-world use, which will test the reassuring trial-phase signal found here against a broader and less closely monitored population. Orforglipron is not yet approved by all regulators; this article describes trial safety data and is not medical advice.

Sources

1. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials — Diabetes, Obesity and Metabolism, 23 June 2026